Table des matières 2007-2008 - IRCM

enhancer". Molecular Endocrinology, 22(7):1633-1646, 2008.hypertension: Part 2 - therapy". CanadianJournal of Cardiology, 24(6): 465-475, 2008.11. Stifani, N., Freitas, A.R.O., Liakhovitskaia, A.,Medvinsky, A., Kania, A., Stifani, S. "Suppressionof interneuron programs and maintenance ofselected spinal motor neuron fates by thetranscription factor AML1/Runx1". Proceedingsof the National Academy of Sciences of theUnited States of America, 105(17): 6451-6456,2008.Autres1. Charron, F., Tessier-Lavigne, M. "The Hedgehog, TGFbeta/BMPand Wnt families of morphogens inaxon guidance". Axon growth and guidance.New York, N.Y.: Landes Bioscience ; SpringerScience, 2007. P. 116-133.6. Kjeldsen, S.E., McInnes, G.T., Mancia, G., Hua, T.A.,Julius, S., Weber, M.A., Coca, A., Girerd, X.,Jamerson, K., Larochelle, P., Macdonald, T.,Schmieder, R.E., Anthony Schork, M., Viskoper,R., Widimsky, J., Zanchetti, A. "Progressiveeffects of valsartan compared with amlodipine inprevention of diabetes according to categories ofdiabetogenic risk in hypertensive patients: TheVALUE trial". Blood Press, 17(3): 170-177, 2008.7. Larochelle, P. "16 e Réunion scientifique annuelle de laSociété québécoise d'hypertension artérielle".Hypertension Canada: 6-7, 2008.8. Larochelle, P. "Pathologie et traitement del'hypertension". Le Patient, 2(1): 12-15, 2008.RECHERCHE CLINIQUE ET BIOÉTIQUE1. Bell, E., Mathieu, G., Racine, E. "The promises of deepbrain stimulation in psychiatry". CanadianPsychiatry Aujourd'hui, 4(4): 14, 2008.2. Bell, E., Racine, E. "Ethics in deep brain stimulation foralcohol dependence". Journal of Neurology,Neurosurgery and Psychiatry: eLetters pourKuhn et collab., 78(10) : 1152-1153, 21 novembre2007.3. Hurlimann, T. "Programme ministériel d’offre dedépistage de la trisomie 21 au Québec : quelsenjeux?" L'Observatoire de la génétique,35(décembre/mars): 2008.4. Karas, M., Larochelle, P., LeBlanc, R.A., Dubé, B.,Nadeau, R., de Champlain, J. "Attenuation ofautonomic nervous system functions inhypertensive patients at rest and duringorthostatic stimulation". Journal of ClinicalHypertension, 10(2): 97-104, 2008.5. Khan, N.A., Hemmelgarn, B., Herman, R.J., Rabkin,S.W., McAlister, F.A., Bell, C.M., Touyz, R.M.,Padwal, R., Leiter, L.A., Mahon, J.L., Hill, M.D.,Larochelle, P., Feldman, R.D., Schiffrin, E.L.,Campbell, N.R.C., Arnold, M.O., Moe, G.,Campbell, T.S., Milot, A., Stone, J.A., Jones, C.,Ogilvie, R.I., Hamet, P., Fodor, G., Carruthers, G.,Burns, K.D., Ruzicka, M., deChamplain, J.,Pylypchuk, G., Petrella, R., Boulanger, J.-M.,Trudeau, L., Hegele, R.A., Woo, V., McFarlane,P., Vallée, M., Howlett, J., Katzmarzyk, P., Tobe,S., Lewanczuk, R.Z. "The 2008 CanadianHypertension Education Programrecommendations for the management of9. Larochelle, P. "Effets indépendants de la baissetensionnelle chez les patients à risque élevé :pertinence de la comparaison d'un ARA et d'uninhibiteur de l'ECA dans la prise en charge del'hypertension au quotidien". L'Hypertension: 7-9, 2008.10. Monassier, L., Laplante, M.-A., Jaffré, F., Bousquet,P., Maroteaux, L., de Champlain, J. "Serotonin 5-HT 2B receptor blockade prevents reactive oxygenspecies-induced cardiac hypertrophy in mice".Hypertension, 52(2): 301-307, 2008.11. Racine, E. "Comment on "Does it make sense tospeak of neuroethics?"". EMBO Reports, 9(1): 2-3, 2008.12. Racine, E. "Which naturalism for bioethics? A defenseof moderate (pragmatic) naturalism". Bioethics,22(2): 92-100, 2008.13. Racine, E. "Interdisciplinary approaches for apragmatic neuroethics". American Journal ofBioethics, 8(1): 52-53, 2008.14. Racine, E. "Enriching our views on clinical ethics:Results of a qualitative study of the moralpsychology of healthcare ethics committeemembers". Journal of Bioethical Inquiry, 5(1):57-67, 2008.15. Racine, E., Amaram, R., Seidler, M., Karczewska, M.,Illes, J. "Media coverage of the persistentvegetative state and end-of-life decision-making".Neurology, 73(11): 1027-1032, 2008.16. Racine, E., DuRousseau, D., Illes, J. "Ethical issues inperformance enhancing technologies: From52